Instead of viewing partnerships like Nvidia and Eli Lilly as a competitive threat, Recursion's CEO sees it as powerful validation for the AI drug discovery space. This activity shifts the industry conversation from skepticism ('Will this work?') to urgency ('Who will win?'), benefiting pioneering companies like Recursion by confirming their founding thesis and attracting more investment and attention to the field.

Moonshot AI overcomes customer skepticism in its AI recommendations by focusing on quantifiable outcomes. Instead of explaining the technology, they demonstrate value by showing clients the direct increase in revenue from the AI's optimizations. Tangible financial results become the ultimate trust-builder.

Focusing on AI for cost savings yields incremental gains. The transformative value comes from rethinking entire workflows to drive top-line growth. This is achieved by either delivering a service much faster or by expanding a high-touch service to a vastly larger audience ("do more").

Coastline Academy frames AI's value around productivity gains, not just expense reduction. Their small engineering team increased output by 80% in one year without new hires by using AI as an augmentation tool. This approach focuses on scaling capabilities rather than simply shrinking teams.

Instead of abstract productivity metrics, define your AI goal in terms of concrete headcount avoidance. Sensei's objective is to achieve the output of a 700-person company with half the staff by using AI to bridge the gap. This makes the ROI tangible and aligns AI investment with scalable, capital-efficient growth.

Since AI can deliver results instantly, customers may perceive the output as low-effort and thus low-quality. To combat this, shift the focus from the speed of delivery to the immense effort, experience, and investment required to build the underlying AI system in the first place.

While most focus on AI for drug discovery, Recursion is building an AI stack for clinical development, where 70% of costs lie. By using real-world data to pinpoint patient locations and causal AI to predict responders, they are improving trial enrollment rates by 1.5x. This demonstrates a holistic, end-to-end AI strategy that addresses bottlenecks across the entire value chain, not just the initial stages.

While AI-driven drug discovery is the ultimate goal, Titus argues its most practical value is in improving business efficiency. This includes automating tasks like literature reviews, paper drafting, and procurement, freeing up scientists' time for high-value work like experimental design and interpretation.

A traditional IT investment ROI model misses the true value of AI in pharma. A proper methodology must account for operational efficiencies (e.g., time saved in clinical trials, where each day costs millions) and intangible benefits like improved data quality, competitive advantage, and institutional learning.